I had hoped that when I looked at the presentations etc I would see good data on HOW the technology has improved - e.g. better vector as per pre-clinical in vivo data, better understanding of where to inject. But they don't seem to address this.
That said, I haven't looked hard for papers yet - and haven't digested the S1 (my bad!).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.